Advertisements

Coversyl 10 mg

Quick links to important sections

Coversyl 10 mg

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Coversyl 10 mg

What is Coversyl 10 mg?

Coversyl 10 mg is a prescription medication that belongs to a class of drugs known as angiotensin-converting enzyme (ACE) inhibitors. The active ingredient in this medication is perindopril arginine.

Mechanism of Action

Perindopril works by inhibiting the action of a specific enzyme in the body that produces angiotensin II, a substance that causes blood vessels to narrow. By reducing the production of this substance, the medication helps blood vessels to relax and widen. This process results in lower blood pressure and makes it easier for the heart to pump blood to the rest of the body.

Therapeutic Use

Coversyl 10 mg is primarily used in the management of cardiovascular health. Its clinical applications include:

  • Hypertension: It is used to treat high blood pressure, helping to maintain levels within a target range.
  • Stable Coronary Artery Disease: It is indicated to reduce the risk of cardiac events, such as heart attacks, in patients with established stable coronary artery disease.
  • Heart Failure: In some cases, it is used to help manage heart failure, a condition where the heart muscle does not pump blood as effectively as it should.

As a long-term treatment, Coversyl 10 mg is intended to help reduce the workload on the cardiovascular system and decrease the long-term risk of complications associated with high blood pressure and heart disease.

Regulatory References

  1. EMA Opinion on Perindopril Indications
Advertisements

What side effects are possible with Coversyl 10 mg?

Possible side effects and safety information

The safety profile of Coversyl (Perindopril) is officially documented by government health authorities, classifying potential adverse reactions by frequency and physiological system affected.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped based on incidence observed in clinical use and trials, according to regulatory standards:

  • Common (1% to 10%): Includes general effects such as dizziness, headache, a persistent cough, and asthenia (weakness). Gastrointestinal effects like abdominal pain, nausea, and diarrhoea are also common.
  • Uncommon (0.1% to 1%): Includes angioedema (swelling of face/extremities), syncope (fainting), mood disturbances, and renal insufficiency.
  • Rare to Very Rare: Serious events are cited, including acute renal failure, hepatitis, and certain serious blood disorders (agranulocytosis).

Serious Safety Considerations

The most serious reaction highlighted in regulatory documents is Angioedema, which involves potentially life-threatening swelling of the tongue or larynx. Additionally, excessive hypotension (low blood pressure) is documented as a risk, which can rarely lead to events such as myocardial infarction or stroke, particularly in high-risk patients.

Population-Specific Constraints

Official labels define constraints for specific patient groups:

  • Pregnancy: The medicine is contraindicated during the second and third trimesters due to documented risk of injury or death to the developing fetus.
  • Renal Impairment: Requires careful monitoring, as there is an increased potential for worsening kidney function or developing hyperkalaemia (high potassium).
  • Patients of African Origin: Regulatory documents note that this population may have an increased risk of developing Angioedema.

Safety notes also indicate that effects like dizziness and hypotension are more likely to occur following the initiation of therapy or during dose increases.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented manifestations of Perindopril overdose and the mandated emergency actions, based strictly on government regulatory labeling (e.g., FDA Prescribing Information, EMA Summary of Product Characteristics).


Documented Overdose Presentations

The most likely clinical presentation of overdose is excessive hypotension (profound low blood pressure), often manifesting as dizziness, lightheadedness, fainting, or confusion. Other documented effects include sickness, cramps, and salt and water disturbances.

Severe Outcomes and Emergency Action

Regulatory labeling documents that excessive hypotension may result in severe complications, including acute renal failure, myocardial infarction (heart attack), or cerebrovascular accident (stroke). The most life-threatening event listed is angioedema (swelling of the glottis or larynx), which may be fatal due to airway obstruction.


When Immediate Medical Help is Required

Seek immediate medical attention for any suspected overdose or symptoms of severe hypotension or swelling. For excessive hypotension, the patient should be placed immediately in a supine position. For airway obstruction due to angioedema, emergency therapy, including the prompt administration of epinephrine and measures to ensure a patent airway, is mandated.

Treatment is symptomatic and supportive, as no specific antidote is known. Supportive measures include volume restoration with intravenous physiological saline. The active metabolite, Perindoprilat, is dialysable for removal from the body.

Advertisements

Therapeutic Uses of Coversyl 10 mg

What Coversyl 10 mg Treats: Main Uses and Benefits

Coversyl 10 mg (Perindopril) is commonly used to help with long-term therapeutic support across major cardiovascular domains, focusing on managing strain and contributing to risk management for critical events. These applications are established for the management of various cardiovascular conditions.

This medication is primarily used for the long-term management of essential hypertension, to address functional limitations associated with symptomatic chronic heart failure, and supports management after a myocardial infarction or in patients with established coronary artery disease.

“Treatment supports easing the overall symptom load and may assist with a sense of stability when chronic cardiovascular conditions are more noticeable.”


Chronic High Blood Pressure and Vascular Strain

In cases of persistently elevated blood pressure that creates noticeble physiological strain, treatment may assist with managing sustained arterial pressure. This supports overall management of the systemic physiological strain associated with hypertension. This approach is often applied during phases when symptoms become more noticeable and supportive relief is needed.


Quick Fact: Relief for Symptomatic Fatigue

Coversyl 10 mg is relevant for managing symptom clusters that interfere with daily functioning, specifically supporting patients who experience reduced exercise tolerance and chronic fatigue associated with heart function issues. Treatment supports easing day-to-day comfort and assists with supporting functional stability for physical activity.

Advertisements

Eligibility and Restrictions for Use

Coversyl 10 mg (perindopril), an Angiotensin-Converting Enzyme (ACE) inhibitor, is a prescription medication primarily used for managing high blood pressure (hypertension) and reducing the risk of cardiovascular events in patients with stable coronary artery disease. It is also prescribed for some patients with heart failure.


Who Cannot Use Coversyl 10 mg (Contraindications)

This medication is contraindicated in several situations due to the risk of serious side effects. You must not take Coversyl 10 mg if you:

  • Have a known allergy or hypersensitivity to perindopril, any other ACE inhibitor, or any of the inactive ingredients.
  • Have a history of angioedema (a severe allergic reaction causing swelling of the face, tongue, or throat) associated with previous ACE inhibitor treatment, or if you have hereditary or idiopathic angioedema.
  • Are pregnant (especially after the first three months) or planning to become pregnant, as it can cause serious harm to the fetus.
  • Are taking a medicine containing aliskiren and have diabetes or impaired kidney function.
  • Are taking sacubitril/valsartan, a medicine for heart failure, due to an increased risk of angioedema. You must not start Coversyl until 36 hours after taking the last dose of sacubitril/valsartan.
  • Are undergoing certain blood filtration treatments (e.g., dialysis using specific high-flux membranes) or LDL apheresis.

When to Use Caution (Precautions)

Inform your doctor before taking this medication if you have:

  • Kidney problems (including renal artery stenosis) or are on dialysis.
  • Liver problems.
  • Aortic stenosis, mitral valve stenosis, or hypertrophic cardiomyopathy (heart muscle disease).
  • Are undergoing desensitisation treatment for insect stings.
  • Are on a salt-restricted diet or using potassium-containing salt substitutes.
Advertisements

What should I know about interactions with other medicines?

Coversyl 10 mg Interactions with other medicines and products

The interaction profile of Coversyl 10 mg (Perindopril) is based strictly on constraints documented in official government regulatory information.

Formally Contraindicated Combinations

Certain combinations are explicitly prohibited due to the risk of severe reactions:

  • Sacubitril/valsartan: Co-administration is contraindicated due to the significantly increased risk of angioedema, requiring a 36-hour separation period before starting Coversyl.
  • Aliskiren: Use is contraindicated specifically in patients with diabetes mellitus or established renal impairment (GFR less than 60 mL/ min/1.73 m^2).
  • Extracorporeal Treatments: Certain procedures, such as high-flux membrane dialysis, are prohibited due to the risk of severe anaphylactoid reactions.

Pharmacodynamic and Exposure Risk Agents

Interactions often center on electrolyte balance and additive blood pressure effects:

  • Agents Affecting Potassium Levels: Medicines and products that increase serum potassium, such as potassium-sparing diuretics (e.g., Triamterene, Amiloride) and potassium supplements, are generally not recommended due to the high risk of hyperkalaemia.
  • Lithium: Co-administration is not recommended due to the potential for a reversible rise in lithium concentrations and resulting toxicity.
  • Food: Ingestion of food officially reduces the bioavailability of the active metabolite, Perindoprilat.

Regulatory documentation also identifies an increased risk of angioedema when Perindopril is combined with mTOR inhibitors (e.g., Sirolimus) and certain Gliptins.

Advertisements

Mechanism of Action

Coversyl 10 mg contains the active substance perindopril, which functions as a prodrug and is hydrolyzed primarily in the liver to its biologically active metabolite, perindoprilat. Perindoprilat exerts its function by specifically binding to and inhibiting the Angiotensin-Converting Enzyme (ACE), also known as kininase II. This enzyme is a key component of the Renin-Angiotensin-Aldosterone System (RAAS).

The primary molecular consequence of ACE inhibition is the blockage of the enzymatic conversion of the inactive peptide Angiotensin I into the potent vasoconstrictor Angiotensin II. This reduction in circulating Angiotensin II concentration subsequently decreases its downstream effects, including the diminished release of aldosterone from the adrenal cortex. Additionally, ACE is responsible for the inactivation of bradykinin, a peptide that induces vasodilation. By inhibiting ACE, perindoprilat causes an accumulation of bradykinin in vascular tissues. The combined effects of reduced Angiotensin II and accumulated bradykinin lead to vasodilation and a subsequent reduction in systemic vascular resistance, modulating pressure within the circulatory system.

Advertisements

Dosage and Administration Information

The use of Coversyl 10 mg, which contains the active substance Perindopril arginine, follows specific administrative principles. The medication is delivered via the oral route as a film-coated tablet.


Dosing and Frequency

Perindopril is administered once daily (single dose) and is typically taken in the morning. The established protocol for therapy involves an initial titration period, starting with a lower dose, generally 5 mg once daily for standard adult use in conditions like hypertension or stable coronary artery disease (SCAD). The dose is subsequently adjusted by a healthcare professional, with the maximum daily dose for these indications being 10 mg. For chronic conditions like hypertension, this medication is typically utilized as a long-term therapy following successful titration.


Administration Conditions

A key procedural requirement is that the tablet should be taken before a meal. Food intake is noted to alter the rate and extent of the conversion of Perindopril to its active form, so adherence to the pre-meal timing is a standard condition of use.


Population-Specific Adjustments

Specific populations require modified initiation protocols. Older adults (typically over 65 years) often start on a reduced dose, usually 2.5 mg once daily. Similarly, patients with renal impairment may require a reduced starting dose to accommodate changes in the body's ability to clear the medication, based on creatinine clearance. If a dose is missed, instructions specify that the user should not take a double dose but should instead take the next scheduled dose at the usual time.

Advertisements

Recent Clinical Evidence

Research Evidence: Overview of Studies for Coversyl 10 mg

The evidence base for Perindopril (the active ingredient in Coversyl 10 mg) is built upon large, long-term clinical trials and systematic reviews that examined chronic cardiovascular conditions. This overview explains the research landscape, focusing on what was studied, the patterns observed, and what remains uncertain. Studies help show what has been observed so far in groups of patients. Findings describe group patterns, and research does not determine whether an individual will respond similarly.


Evidence for Use in Managing Chronic High Blood Pressure

Research related to managing persistently elevated blood pressure was primarily conducted using large-scale, long-term Randomized Controlled Trials (RCTs). Researchers monitored the occurrence of major events like stroke and heart attack over several years to evaluate patterns related to Perindopril. The research evaluated populations of adults diagnosed with essential hypertension, and studies explored patient subgroups with existing vascular conditions, including those with prior stroke. Findings describe patterns observed, indicating changes measured in arterial blood pressure levels during the study period.

Evidence for Use in Established Coronary Artery Disease

Clinical evidence for use in patients with stable vascular conditions comes from pivotal, placebo-controlled RCTs spanning approximately four years of follow-up. Research explored Perindopril, focusing on the measurement of composite cardiovascular endpoints, including cardiovascular death and non-fatal myocardial infarction. Findings described patterns that were observed when comparing the treatment group to the control group. What remains uncertain is the full characterization of outcomes in patients with stable CAD who also have clear, overt symptomatic chronic heart failure, as these patients were frequently excluded from the largest trials.


Evidence for Supporting Symptomatic Chronic Heart Failure

Specific RCTs were evaluated in symptomatic heart failure, including older adults. Studies primarily focused on measuring functional outcomes like changes in the NYHA functional class (a measure of symptom severity) and objective measures like exercise tolerance. Findings were mixed, and evidence suggests certainty remains low for the main long-term composite endpoints of mortality and major morbidity in certain elderly populations, as the key trial was observed in some studies to be underpowered.


Evidence Gaps and Areas of Research Uncertainty

Long-term effects are not fully established for certain specific endpoints, such as available mortality and morbidity data in all elderly heart failure groups, as data are still emerging. Furthermore, data for certain groups remain insufficient, and sample sizes were modest in some specialized trials, meaning subgroup findings are uncertain for some outcomes.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Coversyl 10 mg (FAQ)


Q: What is the main condition or use that Coversyl 10 mg is prescribed for?

A: According to official product information, this medication is prescribed to treat arterial hypertension (high blood pressure) and symptomatic heart failure. Official information also states that the medication is indicated for reducing the risk of cardiovascular events in patients with stable coronary artery disease.


Q: Can Coversyl 10 mg be used for other heart conditions besides high blood pressure, such as heart failure?

A: Yes, official product information lists its indications as including high blood pressure, heart failure, and stable coronary artery disease. Therefore, it is indicated for the treatment of symptomatic heart failure.


Q: How quickly does Coversyl 10 mg typically start to lower blood pressure after the first dose?

A: This medication is designed to be long-acting. The blood pressure-lowering effect is gradual, usually reaching its peak after 4 to 6 hours. The full benefit for chronic conditions is typically assessed over a period of weeks and depends on continuous daily use.


Q: How long does it take to see the maximum effect of Coversyl 10 mg on blood pressure?

A: The maximum or full benefit of the medication may take up to one month of continuous daily dosing to be fully realized. Maximum benefit is often assessed by healthcare providers after a few weeks of consistent use.


Q: Why does Coversyl 10 mg sometimes cause a persistent dry cough?

A: The cough is a known side effect in this class of medication. It is presumed to be caused by the medication's mechanism of action, which involves inhibiting the breakdown of a substance called bradykinin. The accumulation of bradykinin is presumed to lead to irritation and can cause a persistent, dry cough.


Q: Is the cough side effect associated with Coversyl 10 mg permanent?

A: Official safety data indicates that the cough side effect is reversible. The cough generally resolves after the medication is discontinued.


Q: What is the risk of angioedema (swelling) when taking Coversyl 10 mg?

A: Angioedema (rapid swelling of the face, lips, tongue, or throat) is a serious allergic reaction reported with this class of medication. This is a serious reaction noted in regulatory documents that necessitates seeking urgent medical care. It can occur at any time during treatment.


Q: Is angioedema more likely to occur immediately after starting Coversyl 10 mg or later on?

A: According to official safety information, angioedema can occur at any time during treatment. Patients are advised to be aware of the symptoms throughout the course of therapy.


Q: Is feeling dizzy or lightheaded a common experience during the first few days of taking Coversyl?

A: Yes, dizziness and lightheadedness are listed as common side effects reported in clinical trials. They are especially likely to occur at the start of treatment or when the dosage is increased.


Q: Can Coversyl 10 mg cause a noticeable change or loss of taste sensation?

A: Official adverse reaction reports indicate that taste disturbances (known medically as dysgeusia) are a common side effect of the medication.


Q: What kind of headaches are generally reported as a side effect of Coversyl 10 mg?

A: Headache is listed as a common adverse reaction in the nervous system category of reported side effects. If headaches become persistent or severe, this should be discussed with a healthcare provider.


Q: Does taking Coversyl 10 mg often lead to feelings of fatigue or lack of energy?

A: Yes, both fatigue and general lack or loss of strength are listed in official documents as common side effects reported by some patients.


Q: Can Coversyl 10 mg lead to digestive issues such as diarrhea or upset stomach?

A: Official safety data confirms that common gastrointestinal side effects can occur. These may include diarrhea, nausea, vomiting, abdominal pain, and indigestion.


Q: Is it possible for Coversyl 10 mg to cause a skin rash or other dermatological reactions?

A: Yes, official adverse reaction information lists a rash and pruritus (itching) as common dermatologic side effects that may occur.


Q: Do initial side effects like dizziness tend to lessen or go away after the body adjusts to Coversyl 10 mg?

A: Regulatory documents indicate that symptoms like dizziness, which may be related to low blood pressure, are more likely to occur at the start of treatment. This suggests that the severity or frequency may lessen over time.


Q: Is Coversyl considered less effective in people of African descent compared to other groups?

A: Official product information notes that, based on clinical data, this medication may be less effective in lowering blood pressure in patients of African origin compared to non-black patients. Additionally, these patients may also have a higher risk of angioedema.


Q: Why is it generally recommended to avoid NSAIDs (like ibuprofen) while taking Coversyl 10 mg?

A: Concomitant use with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) can increase the risk of worsening kidney function. This combination is generally advised against due to the potential for adverse effects on the kidneys.


Q: How does alcohol consumption potentially interact with the effects of Coversyl 10 mg?

A: Official warnings state that alcohol consumption can increase the blood pressure-lowering effect of the medication. This can potentially cause excessive dizziness or lightheadedness.


Q: What is the general guidance on using Coversyl 10 mg if a patient has a history of angioedema?

A: The medication is contraindicated if a patient has a history of angioedema (swelling) associated with any previous ACE inhibitor therapy. This is a safety restriction noted in official regulatory documents.


Q: What is the risk profile for Coversyl 10 mg in patients with severe liver disease?

A: Official documentation indicates that the medication should be used with caution in patients with pre-existing liver problems. Warnings are noted regarding the serious risk of hepatic failure.


Q: Can Coversyl 10 mg be taken with other types of blood pressure medication, such as calcium channel blockers?

A: Official product information states that the medication can be used alone as monotherapy or in combination with other classes of blood pressure medications. The use of this medication in combination with diuretics requires clinical review.


Q: Is there any established safety information on the use of Coversyl 10 mg in children or adolescents?

A: The safety and effectiveness of this medication in children and adolescents have not been established through clinical trials. Therefore, its use in this age group is not recommended in the regulatory documents.


Q: What is the official guidance on taking Coversyl 10 mg while pregnant or breastfeeding?

A: This medication is contraindicated during the second and third trimesters of pregnancy due to the risk of serious harm or death to the fetus. It is also not recommended for mothers who are breastfeeding.


Q: Is it true that Coversyl 10 mg may reduce blood pressure too much when used with general anesthesia for surgery?

A: Regulatory warnings note that patients who are scheduled for anesthesia and/or major surgery should communicate this with their care team, as the medication may increase the risk of a severe drop in blood pressure (hypotension) during these procedures.


Q: Can Coversyl 10 mg affect a person's ability to safely drive or operate machinery?

A: Due to the risk of dizziness or weakness related to low blood pressure, official documents caution that the ability to drive or operate machinery may be impaired, particularly when starting treatment or after a dose change.


Q: What is the general advice if a person develops severe vomiting or diarrhea while taking Coversyl 10 mg?

A: Regulatory documents state that experiencing severe or continuing vomiting or diarrhea should be reported to a healthcare provider promptly, as fluid and salt loss can lead to low blood pressure.


Q: Is Coversyl 10 mg used for kidney protection in patients with conditions like diabetes?

A: This class of medication can offer benefits to patients with specific kidney conditions related to blood pressure management. This renoprotective effect is a factor considered by healthcare providers when treating conditions like diabetes.


Q: Is it necessary to have blood tests done regularly while taking Coversyl 10 mg?

A: Regulatory guidance suggests regular monitoring of certain laboratory parameters during therapy. Monitoring often includes checks of serum potassium levels and kidney function (creatinine and urea).


Q: Is shortness of breath a potential adverse effect related to Coversyl 10 mg?

A: Shortness of breath is noted in the adverse reaction profile. This can be a general symptom, or a symptom of the serious condition angioedema.


Q: What is the official information regarding the lactose content in Coversyl tablets?

A: Official product information, such as the Summary of Product Characteristics (SmPC), states that Coversyl tablets contain the excipient lactose.


Q: Is it possible for Coversyl to cause muscle cramps or joint pain?

A: Official adverse reaction lists include both muscle cramps and joint pain (arthralgia) as reported side effects.


Q: Why are people with narrowed kidney arteries (renal artery stenosis) cautioned against using Coversyl 10 mg?

A: The medication is generally contraindicated or requires extreme caution in patients with renal artery stenosis (narrowing of the arteries supplying the kidney with blood) due to the risk of worsening kidney function.


Q: Can the feeling of lightheadedness from Coversyl be worsened by sweating heavily or being dehydrated?

A: Conditions that cause fluid or salt loss, such as severe sweating, vomiting, or diarrhea, can lead to a drop in blood pressure. This drop in pressure may be associated with worsened feelings of dizziness or lightheadedness.


Q: Does Coversyl 10 mg require a special storage condition or is it stored at room temperature?

A: Official storage instructions state that the medication should be stored in its original packaging below 25 C and protected from moisture, heat, and sunlight.


Q: Is the use of Coversyl 10 mg appropriate for the elderly population?

A: The medication can generally be used safely by elderly people (over 65). However, regulatory guidance notes that a lower starting dose may be considered if there is reduced kidney function.


Q: Are there any specific dietary restrictions to be aware of when taking Coversyl 10 mg?

A: The tablet should be taken before a meal. Patients on a salt-restricted diet or using potassium-containing salt substitutes are advised to be aware of the increased risk of high potassium levels.


Q: What are the symptoms of having too much potassium (hyperkalemia) when taking Coversyl 10 mg?

A: High potassium levels (hyperkalaemia) can be serious. Symptoms associated with hyperkalaemia may include an irregular heartbeat, numbness or tingling in the hands, feet, or lips, and unusual weakness.


Q: What is the general information regarding Coversyl 10 mg and possible effects on kidney function?

A: Renal function should be monitored periodically. Use requires careful monitoring in patients with existing kidney impairment, and it is contraindicated in patients with certain kidney circulation issues, such as renal artery stenosis.


Q: What is the nature of the interaction between Coversyl 10 mg and diuretics (water pills)?

A: Concomitant use with diuretics can increase the risk of a significant drop in blood pressure (symptomatic hypotension). The use of this medication in combination with diuretics requires clinical review.


Q: What is the difference in action or effect between Coversyl 5 mg and Coversyl 10 mg?

A: Both tablets contain the same active substance. The 5 mg strength is generally used as the starting dose during the titration period, while 10 mg is often the maximum dose for certain indications, as determined by a healthcare professional.


Q: Are there research studies supporting the use of Coversyl 10 mg for preventing major cardiac events?

A: The medication is indicated for the reduction of the risk of cardiac events in patients with a history of myocardial infarction (heart attack) and/or revascularization (stable coronary artery disease). This indication is supported by clinical studies.


Q: Can the medication affect blood sugar control in people with diabetes?

A: Official documents note that patients with diabetes who are taking insulin or oral diabetic medications must have their blood sugar control closely monitored during the first month of treatment with this medication.


Q: What are the non-promissory expectations for long-term health benefits of Coversyl 10 mg?

A: Expected long-term benefits include the management of high blood pressure and the reduction of cardiovascular risk in patients with stable coronary artery disease, according to the official indications.

Advertisements

How should Coversyl 10 mg be stored and disposed of?

How to Store and Dispose of Coversyl 10 mg

Coversyl 10 mg (perindopril arginine) must be stored according to specific regulatory requirements to maintain its stability.


Storage Conditions

Store the tablets at room temperature, specifically below 30 C (86 F). The medicine must not be refrigerated or frozen. To protect the moisture-sensitive tablets, the bottle must be kept tightly closed in the original container and stored away from light.

Disposal Instructions

Keep the medicine out of the reach and sight of children. Do not use the product after the expiration date. Unused or expired tablets must not be disposed of via wastewater or household waste; instead, they should be returned to a pharmacist for appropriate pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coversyl 10 mg found in:

A-Z Index: